<?xml version="1.0" encoding="UTF-8"?><MedicinalProductIndication xmlns="http://hl7.org/fhir"><id value="80efee93-8d5a-4f98-aba7-ed1a8e88e0fc"/><meta><versionId value="1"/><lastUpdated value="2022-02-17T17:34:54.818+08:00"/><tag><system value="http://terminology.hl7.org/CodeSystem/v3-ActReason"/><code value="HTEST"/><display value="test health data"/></tag></meta><diseaseSymptomProcedure><coding><system value="http://ema.europa.eu/example/indicationasdisease-symptom-procedure"/><code value="Venousthromboembolismprophylaxis"/></coding><text value="Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip\nor knee replacement surgery.\nPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation\n(NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age\n≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).\nTreatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent\nDVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients)."/></diseaseSymptomProcedure><comorbidity><coding><system value="http://ema.europa.eu/example/comorbidity"/><code value="Hipsurgery"/></coding></comorbidity><intendedEffect><coding><system value="http://ema.europa.eu/example/intendedeffect"/><code value="PRYLX"/></coding></intendedEffect><population><ageRange><low><value value="18"/><unit value="a"/></low></ageRange></population></MedicinalProductIndication>